Reply To: Bortezomib During DI for T Cell Lymphoma

  • Katherine Trimble

    Member
    May 9, 2022 at 10:45 am

    Thank you, our plan is to start induction with the 1231 with Bortezomib and switch to the 0434 as well.
    We ended up needing to get Bortezomib from the drug company due to insurance denial.

    ——————————
    Katherine Trimble, CPHON,CPNP,MSN,RN
    Pediatric Oncology Nurse Educator
    Winfield, IL
    United States
    ——————————
    ——————————————-
    Original Message:
    Sent: 05-06-2022 12:37 PM
    From: Shari Feinberg
    Subject: Bortezomib During DI for T Cell Lymphoma

    We also use 1231 induction without Bortezomib and switch to AALL 0434 from consolidation forward.  We will adjust our approach when data is final.

    ——————————
    Shari Feinberg, ARNP, CPNP-PC, CPON
    Pediatric Hematology Oncology Nurse Practitioner
    Maimonides Children’s Hospital
    Brooklyn, NY
    ——————————

    Original Message:
    Sent: 05-06-2022 09:04 AM
    From: Maureen Lynch Baker
    Subject: Bortezomib During DI for T Cell Lymphoma

    We use the 1231 induction without Bortezomib and then switch to AALL0434 starting with consolidation. The data on the 1231 comparing the regular induction with Bortezomib is not final, so we are using the standard induction for that protocol.

     

    Maureen Baker APN, MSN, PCNS-BC, CPNP, CPON

    Pediatric Hematology/Oncology Advanced Practice Nurse

    Valerie Fund Childrens Center

    Goryeb Childrens Hospital

    Atlantic Health Systems

    973-971-6720 (P)

    973-290-7171 (F)

    Maureen.baker@atlantichealth.org

     

    Original Message:
    Sent: 5/5/2022 8:31:00 PM
    From: Breanne Roche
    Subject: RE: Bortezomib During DI for T Cell Lymphoma

    Hi Kathy,

    We have not been using it routinely for newly diagnosed patients, it is not our standard of care, so I cannot help you! Do you plan on using it during Induction and DI for your patient? 

    I am curious to see what institutions have transitioned it as their standard of care!

    Breanne 

    ——————————
    Breanne Roche, DNP, RN, CPNP
    Pediatric Nurse Practitioner
    Rainbow Babies & Children’s Hospital
    Cleveland, Ohio

    Original Message:
    Sent: 05-05-2022 02:13 PM
    From: Katherine Trimble
    Subject: Bortezomib During DI for T Cell Lymphoma

    HI Breanne,
    We have a newly diagnosed patient with T-cell lymphoma. WE are planning to give the bortezomib 1.4.8 and 11.
    We are having difficulty getting insurance approval. BCBS. We did a peer to peer.  Send references.
    Did you have difficulty? Do you have any suggestions?
    Thank you,
    Kathy Trimble MSN, RN, CPNP
    Pediatric Hematology/Oncology Nurse Practitioner
    Northwestern Medicine Central DuPage Hospital
    Winfield, IL

    ——————————
    Katherine Trimble, CPHON,CPNP,MSN,RN
    Pediatric Oncology Nurse Educator
    Winfield, IL
    United States

    Original Message:
    Sent: 05-05-2022 12:48 PM
    From: Breanne Roche
    Subject: Bortezomib During DI for T Cell Lymphoma

    Hi,

    I was wondering what institutions are using bortezomib during DI for T Cell lymphoma patients. If you are using it, are you giving it on Days 1, 4, 8, & 11?

    Thanks, 

    Bre

    ——————————
    Breanne Roche, DNP, RN, CPNP
    Pediatric Nurse Practitioner
    Rainbow Babies & Children’s Hospital
    Cleveland, Ohio
    ——————————